HK1259382A1 - 藥物製劑及其用於治療色素性視網膜炎的用途 - Google Patents

藥物製劑及其用於治療色素性視網膜炎的用途

Info

Publication number
HK1259382A1
HK1259382A1 HK19101750.7A HK19101750A HK1259382A1 HK 1259382 A1 HK1259382 A1 HK 1259382A1 HK 19101750 A HK19101750 A HK 19101750A HK 1259382 A1 HK1259382 A1 HK 1259382A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pharmaceutical formulations
retinitis pigmentosa
pigmentosa
retinitis
Prior art date
Application number
HK19101750.7A
Other languages
English (en)
Inventor
Rosa Mario De
Original Assignee
Kaleyde Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaleyde Pharmaceuticals Ag filed Critical Kaleyde Pharmaceuticals Ag
Publication of HK1259382A1 publication Critical patent/HK1259382A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK19101750.7A 2016-01-12 2019-01-31 藥物製劑及其用於治療色素性視網膜炎的用途 HK1259382A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUB2016A009937A ITUB20169937A1 (it) 2016-01-12 2016-01-12 Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
PCT/EP2017/050497 WO2017121766A1 (en) 2016-01-12 2017-01-11 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa

Publications (1)

Publication Number Publication Date
HK1259382A1 true HK1259382A1 (zh) 2019-11-29

Family

ID=55806719

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101750.7A HK1259382A1 (zh) 2016-01-12 2019-01-31 藥物製劑及其用於治療色素性視網膜炎的用途

Country Status (13)

Country Link
US (1) US20180353565A1 (zh)
EP (1) EP3402504A1 (zh)
JP (1) JP2019504006A (zh)
KR (1) KR20180100574A (zh)
CN (1) CN108463237A (zh)
AU (1) AU2017206626A1 (zh)
CA (1) CA3011077A1 (zh)
HK (1) HK1259382A1 (zh)
IL (1) IL260517B (zh)
IT (1) ITUB20169937A1 (zh)
RU (1) RU2018125290A (zh)
WO (1) WO2017121766A1 (zh)
ZA (1) ZA201804589B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202015718A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 視網膜色素變性治療用胜肽
IT202200007754A1 (it) 2022-04-19 2023-10-19 Iridea S R L Nuovi composti con attivita’ farmacologica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236157A1 (en) 1995-11-29 1997-06-05 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product
WO1998018471A1 (fr) 1996-10-28 1998-05-07 Senju Pharmaceutical Co., Ltd. Medicaments pour le traitement des troubles circulatoires oculaires
FR2784898A1 (fr) 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
WO2003007979A1 (en) 2001-07-18 2003-01-30 Board Of Regents, The University Of Texas System An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
JP4953040B2 (ja) 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤
CA2615444A1 (en) 2005-07-15 2007-01-25 Donald J. Baker Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
ITMI20061607A1 (it) * 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2009089399A2 (en) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
WO2009111169A2 (en) 2008-02-29 2009-09-11 Bausch & Lomb Incorporated Compositions comprising pkc-delta modulators and methods for ocular neuroprotection
CA2729605A1 (en) 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
JP2012062258A (ja) 2010-09-14 2012-03-29 Oriza Yuka Kk 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤
KR102014524B1 (ko) 2011-04-26 2019-08-26 레트로토프 인코포레이티드 산화성 망막 질환
WO2014100433A1 (en) * 2012-12-19 2014-06-26 Brown University Methods for treatment of microcephaly associated autism disorders
WO2014100361A1 (en) 2012-12-19 2014-06-26 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
CA2992662A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists

Also Published As

Publication number Publication date
RU2018125290A3 (zh) 2020-06-22
JP2019504006A (ja) 2019-02-14
AU2017206626A1 (en) 2018-07-26
US20180353565A1 (en) 2018-12-13
RU2018125290A (ru) 2020-02-13
KR20180100574A (ko) 2018-09-11
EP3402504A1 (en) 2018-11-21
WO2017121766A1 (en) 2017-07-20
ITUB20169937A1 (it) 2017-07-12
CA3011077A1 (en) 2017-07-20
ZA201804589B (en) 2019-09-25
IL260517B (en) 2020-04-30
CN108463237A (zh) 2018-08-28

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
EP3390642A4 (en) COMPOSITIONS AND METHODS OF TREATING RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
IL261444A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
ZA201900960B (en) Methods and compositions for the treatment of cancer
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
HK1247963A1 (zh) 用於hiv的治療的基因療法及其用途
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
EP3468540A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
IL269400A (en) Medicines and preparations for the treatment of eye disorders
IL265824A (en) Methods and pharmaceutical compositions for the treatment of kidney cancer
HK1259382A1 (zh) 藥物製劑及其用於治療色素性視網膜炎的用途
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3563856A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF
EP3525787A4 (en) TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512
EP3471775A4 (en) HEMOGLOBIN-TARGETED DRUG ADMINISTRATION FOR CANCER TREATMENT
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases